Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has issued an announcement.
ImmuneOnco Biopharmaceuticals has received a second payment of $5 million from Axion Bio as part of their license and collaboration agreement, totaling $20 million received so far. This milestone strengthens their collaboration and supports further advancements in their cancer-targeting therapies, with potential future payments of up to $30 million anticipated.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. operates in the biopharmaceutical industry, focusing on the development of innovative therapies targeting cancer. Its primary products include IMM2510, a bispecific molecule targeting VEGF and PD-L1, and IMM27M, a CTLA-4 antibody, both aimed at enhancing immune responses against tumors.
Average Trading Volume: 6,231,019
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.07B
Learn more about 1541 stock on TipRanks’ Stock Analysis page.